arrow_back Back to App

Polycystic Kidney Disease Awareness Day: Boosting Understanding of the Condition

The U.S. Senate designated September 4, 2022, as National Polycystic Kidney Disease Awareness Day. This aims to increase public understanding of this genetic kidney disorder, which affects hundreds of thousands, and highlight the need for more research and support for patients and their families. This initiative helps citizens better grasp the disease and its life impact.
Key points
Designating Polycystic Kidney Disease Awareness Day seeks to enhance general knowledge about this condition, potentially aiding early detection and better management.
Highlighting that the disease affects individuals of all ages and backgrounds, with a focus on disparities in treatment access for racial and ethnic minorities.
Encouraging support for disease research and educational efforts, which could lead to new treatments and improved quality of life for patients.
article Official text account_balance Process page
Adopted
Citizen Poll
No votes cast
Additional Information
Print number: 117_SRES_816
Sponsor: Sen. Blunt, Roy [R-MO]
Process start date: 2022-09-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

A resolution designating September 4, 2022, as "National Polycystic Kidney Disease Awareness Day", and raising awareness and understanding of polycystic kidney disease.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_SRES_816.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-09-29.

What are the main provisions?

Key points include:

  • Designating Polycystic Kidney Disease Awareness Day seeks to enhance general knowledge about this condition, potentially aiding early detection and better management.
  • Highlighting that the disease affects individuals of all ages and backgrounds, with a focus on disparities in treatment access for racial and ethnic minorities.
  • Encouraging support for disease research and educational efforts, which could lead to new treatments and improved quality of life for patients.
What is the specific legal status?

The current status is Adopted.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Blunt, Roy [R-MO].

What is the latest detailed status?

The latest detailed status is: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S6052-6053; text: CR S5558)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health